Bisphosphonate
Pregnancy: Contraindicated — teratogenic potential. Use calcium and vitamin D in pregnancy.
Risedronate Sodium
Brand names: Actonel, Actonel Once a Week
Adult dose
Dose: Osteoporosis: 35mg once weekly or 5mg OD. Paget's disease of bone: 30mg OD for 2 months.
Route: Oral
Frequency: Once weekly (35mg) or once daily (5mg)
Max: 35mg once weekly; 30mg OD (Paget's)
Administration: same as alendronate — take on empty stomach, upright, 30 minutes before food/drink/drugs. Alternative to alendronate when GI intolerance occurs — slightly better GI tolerability profile. Same bone protection efficacy as alendronate (head-to-head comparisons).
Paediatric dose
Route: Oral
Frequency: Weekly or daily
Max: Individualised
Not licensed under 18 years. Seek specialist paediatric metabolic bone opinion.
Dose adjustments
Renal
eGFR <30: avoid.
Hepatic
No dose adjustment required.
Clinical pearls
- Preferred over alendronate in patients with GI intolerance — has similar efficacy with marginally better oesophageal tolerability
- Same ONJ and atypical fracture warnings apply — inform dentist, consider drug holiday after 5 years oral use
- Correct calcium and vitamin D deficiency before initiation — hypocalcaemia risk if deficient patient given bisphosphonate
- Monthly and quarterly formulations available — useful for adherence issues
Contraindications
- eGFR <30
- Hypocalcaemia
- Oesophageal disease
- Inability to remain upright 30 minutes
- Hypersensitivity to risedronate
Side effects
- Oesophageal irritation (less than alendronate)
- GI upset
- Hypocalcaemia
- ONJ (rare)
- Atypical femoral fractures (long-term)
- Musculoskeletal pain
Interactions
- Calcium, antacids — chelate risedronate; separate by ≥2 hours
- NSAIDs — additive GI risk
Monitoring
- DEXA scan baseline and 2-yearly
- Calcium and vitamin D
- eGFR
- Dental review
Reference: BNFc; BNF 90; NICE CG146 (Osteoporosis). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016